Abstract
Background: Alpha 1 antitrypsin deficiency (AATD) is an autosomal codominant genetic condition that affects Caucasians of the European population due to the presence of a deficient allele of the SERPINA1 gene. A frequency of about 1/5,000 individuals has been estimated in Italy. Objectives: The aim of the study was to evaluate the distribution of the clinical manifestations of severe and intermediate genetic AATD in the geographic area around Parma in Northern Italy. Method: 238 subjects were submitted to molecular analysis of the SERPINA1 gene, and data on anthropometric variables, smoking habits, number of packs per year, AAT serum concentration, and clinical manifestations were recorded and presented as mean ± SD or median values (1st quartile; 3rd quartile). Results: The results show a distribution of genetic AATD of 4.1% of the screened population in the area encompassing the city of Parma. PI*MS and PI*MZ were the most common genotypes at 40.9% and 28.2% of the population with genetic AATD, and asthma and emphysema were the most represented clinical manifestations. Conclusion: Our study allowed to increase the knowledge of the distribution of genetic AATD in Northern Italy providing information regarding frequencies of genotypes and clinical manifestations of the disorder.
References
1.
Gadek
J
, Fells
R
, Zimmerman
G
, Rennard
S
, Crystal
R
. Antielastases of the human alveolar structures. Implications for the protease-antiprotease theory of emphysema
. J Clin Invest
. 1981
;68
:889
–98
. .2.
Aiello
M
, Frizzelli
A
, Pisi
R
, Fantin
A
, Ghirardini
M
, Marchi
L
, Alpha-1 antitrypsin deficiency is significantly associated with atopy in asthmatic patients
. J Asthma
. 2020
;22
:1
–8
. .3.
Ranes
J
, Stoller
JK
. A review of alpha1-antitrypsin deficiency
. Am J Respir Crit Care Med
. 2012
;185
(3
):246
–59
.4.
Poller
W
, Merklein
F
, Schneider-Rasp
S
, Haack
A
, Fechner
H
, Wang
H
, Molecular characterisation of the defective alpha 1-antitrypsin alleles PI Mwurzburg (Pro369Ser), Mheerlen (Pro369Leu), and Q0lisbon (Thr68Ile)
. Eur J Hum Genet
. 1999
;7
:321
–31
. .5.
Lomas
DA
, Hurst
JR
, Gooptu
BJ
. Update on alpha-1 antitrypsin deficiency: new therapies
. J Hepatol
. 2016 Aug
;65
(2
):413
–24
. .6.
BrantlyPaul
MLD
, Paul
BH
, Miller
RT
, Falk
M
, Wu
RG
, Crystal
RG
. Clinical features and history of the destructive lung disease associated with alpha-1-antitrypsin deficiency of adults with pulmonary symptoms
. Am Rev Respir Dis
. 1988
;138
:327
–36
. .7.
de Serres
FJ
, Blanco
I
, Fernández-Bustillo
E
. Genetic epidemiology of alpha-1 antitrypsin deficiency in southern Europe: France, Italy, Portugal and Spain
. Clin Genet
. 2003
;63
(6
):490
–509
. .8.
Ferrarotti
I
, Thun
GA
, Zorzetto
M
, Ottaviani
S
, Imboden
M
, Schindler
C
, Serum levels and genotype distribution of α1-antitrypsin in the general population
. Thorax
. 2012
;67
(8
):669
–74
. .9.
Miravitlles
M
, Dirksen
A
, Ferrarotti
I
, Koblizek
V
, Lange
P
, Mahadeva
R
, European Respiratory Society statement: diagnosis and treatment of pulmonary disease in α1-antitrypsin deficiency
. Eur Respir J
. 2017
;50
:1700610
. .10.
Gorrini
M
, Ferrarotti
I
, Lupi
A
, Bosoni
T
, Mazzola
P
, Scabini
R
, Validation of a rapid, simple method to measure alpha1-antitrypsin in human dried blood spots
. Clin Chem
. 2006
;52
(5
):899
–901
. .11.
Johansson
SGO
, Bieber
T
, Dahl
R
, Friedmann
PS
, Lanier
BQ
, Lockey
RF
, Revised nomenclature for allergy for global use: report of the Nomenclature Review Committee of the World Allergy Organization, October 2003
. J Allergy Clin Immunol
. 2004
;113
:832
–6
. .12.
Global Initiative for Asthma (GINA)
. Global strategy for asthma management and prevention
. 2018
. Available from: www.ginasthma.org.13.
American Thoracic Society
; European Respiratory Society
. American Thoracic Society/European Respiratory Society statement: standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency
. Am J Respir Crit Care Med
. 2003
;168
(7
):818
–900
. .14.
Balderacchi
AM
, Barzon
V
, Ottaviani
S
, Corino
A
, Zorzetto
M
, Wencker
M
, Comparison of different algorithms in laboratory diagnosis of alpha1-antitrypsin deficiency
. Clin Chem Lab Med
. 2021 Mar 5
;59
(8
):1384
–91
. .15.
de Serres
FJ
, Blanco
I
. Prevalence of α1-antitrypsin deficiency alleles PI*S and PI*Z worldwide and effective screening for each of the five phenotypic classes PI*MS, PI*MZ, PI*SS, PI*SZ, and PI*ZZ: a comprehensive review
. Ther Adv Respir Dis
. 2012 Oct
;6
(5
):277
–95
. .16.
Lomas
D
, Evans
D
, Finch
J
, Carrell
R
. The mechanism of Z alpha 1-antitrypsin accumulation in the liver
. Nature
. 1992
;357
:605
–7
. .17.
Luisetti
M
, Seersholm
N
. Alpha1-antitrypsin deficiency. 1: epidemiology of alpha1-antitrypsin deficiency
. Thorax
. 2004
;59
:164
–9
. .18.
Italian registry of patients with alpha-1 antitrypsin deficiency. Available from: http://alfa1antitripsina.it/it.
19.
Giacopuzzi
E
, Laffranchi
M
, Berardelli
R
, Ravasio
V
, Ferrarotti
I
, Gooptu
B
, Real-world clinical applicability of pathogenicity predictors assessed on SERPINA1 mutations in alpha-1-antitrypsin deficiency
. Hum Mutat
. 2018
;39
:1203
–13
. .20.
Annunziata
A
, Ferrarotti
I
, Coppola
A
, Lanza
M
, Imitazione
P
, Spinelli
S
, Alpha-1 antitrypsin screening in a selected cohort of patients affected by chronic pulmonary diseases in Naples, Italy
. J Clin Med
. 2021 Apr 7
;10
(8
):1546
. .21.
Vogelmeier
CF
, Criner
GJ
, Martinez
FJ
, Anzueto
A
, Barnes
PJ
, Bourbeau
J
, Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report: GOLD executive summary
. Eur Respir J
. 2017
;49
(3
):1700214
. .© 2022 S. Karger AG, Basel
2022
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
